Publikation

Limitations of sniff nasal pressure as an outcome measurement in amyotrophic lateral sclerosis patients in a clinical trial

Wissenschaftlicher Artikel/Review - 28.07.2012

Bereiche
PubMed
DOI

Zitation
Bauer M, Czell D, Hartmann S, Goldman B, Müller D, Weber M. Limitations of sniff nasal pressure as an outcome measurement in amyotrophic lateral sclerosis patients in a clinical trial. Respiration 2012; 84:306-11.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Respiration 2012; 84
Veröffentlichungsdatum
28.07.2012
eISSN (Online)
1423-0356
Seiten
306-11
Kurzbeschreibung/Zielsetzung

BACKGROUND
The forced vital capacity (FVC) is an established measure in amyotrophic lateral sclerosis (ALS) clinical trials. Recently the sniff nasal inspiratory pressure (SNIP) test has been increasingly used as a respiratory measure.

OBJECTIVES
It was the aim of this study to assess the feasibility of SNIP as an outcome measure in a phase III clinical trial with a lead-in design.

METHODS
Twenty patients were enrolled in a randomized clinical trial. FVC, SNIP in sitting (SNIPsitt) and supine (SNIPsup) positions, and the ALS functional rating scale score (ALSFRS-R) were measured every 4 weeks.

RESULTS
Complete data were available for 19 patients over 5 months. Baseline values were normal for FVC (101 ± 14%) but abnormal for SNIPsitt and SNIPsup (84 ± 34% and 82 ± 33%). While FVC and ALSFRS-R declined in parallel, SNIPsitt measures declined significantly less compared to ALSFRS-R (p < 0.05) and FVC (p < 0.001) up to 4 months after enrollment. Over 50% of patients still had values equal to or above baseline SNIPsitt measures after 3 months despite abnormal baseline values.

CONCLUSIONS
The delayed decline in SNIP measurements suggests a learning effect over time. The optimal number of SNIPs in ALS clinical trials has yet to be determined. SNIP measures should be used with caution in trials with a lead-in design.